FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Friday

 

Teva Reports First Quarter 2014 Results for Copaxone

Global sales of Copaxone (20 mg/mL and 40 mg/mL), the leading multiple sclerosis therapy in the U.S. and globally, increased 1% compared to the first quarter of 2013. In the United States, sales increased 1% to $816 million following a price increase in January 2014. Sales outside the United States amounted to $254 million, a decrease of 2% in both U.S. dollar and local currency terms, compared to the first quarter of 2013. The decrease reflects the timing of tenders in Russia, which took place in the first quarter of 2013 but not in the first quarter of 2014, and was partially offset by higher sales in Europe.

As of April 18, 2014, Copaxone 40 mg/mL U.S. market share in terms of total prescriptions was 10.5%. Our U.S. market share for the two Copaxone products in terms of total prescriptions was 33.5%, with Copaxone 40 mg/mL then accounting for 31% of total Copaxone prescriptions.

Story Source: The above story is based on materials provided by PHARMACY CHOICE
Note: Materials may be edited for content and length

Labels:



Go to Newer News Go to Older News